![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
A Ibrahimi, L Teboul, D Gaillard, EZ Amri, G Ailhaud, P Young, MA Cawthorne and PA Grimaldi
Centre de Biochimie, UMR 134 CNRS, Universite de Nice-Sophia Antipolis, Faculte des Sciences, France.
In diabetic rodents, thiazolidinediones are able to improve insulin sensitivity of target tissues and to reverse, at least partially, the diabetic state. The effects of these drugs on phenotypic expression in various tissues, including adipose tissue, have been reported. We report here that a new thiazolidinedione compound, BRL 49653, exerts, in preadipose cells, potent effects on the expression of genes encoding proteins involved in fatty acid metabolism. These effects of BRL 49653 in Ob 1771 preadipose cells are similar, in terms of kinetics, reversibility, specificity of genes affected, and requirement for protein synthesis, to those already described for natural or nonmetabolizable fatty acids. Moreover, when used at submaximally effective concentrations, BRL49653 and 2-bromopalmitate act in an additive manner to induce gene expression in preadipose cells, but this additivity of effects is lost when one of the compounds is used at a maximally effective concentration. These observations, suggesting similar mechanisms of action for thiazolidinediones and fatty acids, are strongly supported by the demonstration that (i) both molecules activate, in a heterogolous trans-activation assay, the same nuclear receptor of the steroid/thyroid hormone nuclear receptor superfamily and (ii) transfection of 3T3-C2 fibroblasts with an expression vector for this nuclear receptor confers thiazolidinedione inducibility of adipocyte lipid-binding protein gene expression.
This article has been cited by other articles:
|
|
 |
|
  S. S. T. Lee, W.-Y. Chan, C. K. C. Lo, D. C. C. Wan, D. S. C. Tsang, and W.-T. Cheung Requirement of PPAR{alpha} in maintaining phospholipid and triacylglycerol homeostasis during energy deprivation J. Lipid Res., November 1, 2004; 45(11): 2025 - 2037. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. D. Tchoukalova, M. G. Sarr, and M. D. Jensen Measuring committed preadipocytes in human adipose tissue from severely obese patients by using adipocyte fatty acid binding protein Am J Physiol Regulatory Integrative Comp Physiol, November 1, 2004; 287(5): R1132 - R1140. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. P.H. van Wijk, E. J.P. de Koning, E. P. Martens, and T. J. Rabelink Thiazolidinediones and Blood Lipids in Type 2 Diabetes Arterioscler. Thromb. Vasc. Biol., October 1, 2003; 23(10): 1744 - 1749. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Massiera, P. Saint-Marc, J. Seydoux, T. Murata, T. Kobayashi, S. Narumiya, P. Guesnet, E.-Z. Amri, R. Negrel, and G. Ailhaud Arachidonic acid and prostacyclin signaling promote adipose tissue development: a human health concern? J. Lipid Res., February 1, 2003; 44(2): 271 - 279. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Wagner Early Clinical Development of Pharmaceuticals for Type 2 Diabetes Mellitus: From Preclinical Models to Human Investigation J. Clin. Endocrinol. Metab., December 1, 2002; 87(12): 5362 - 5366. [Full Text] [PDF]
|
|
|
|
 |
|
 J.-C. Sanchez, V. Converset, A. Nolan, G. Schmid, S. Wang, M. Heller, M. V. Sennitt, D. F. Hochstrasser, and M. A. Cawthorne Effect of Rosiglitazone on the Differential Expression of Diabetes-associated Proteins in Pancreatic Islets of C57Bl/6 lep/lep Mice Mol. Cell. Proteomics, July 1, 2002; 1(7): 509 - 516. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Walczak and P. Tontonoz PPARadigms and PPARadoxes: expanding roles for PPAR{gamma} in the control of lipid metabolism J. Lipid Res., February 1, 2002; 43(2): 177 - 186. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Helledie, M. Antonius, R. V. Sørensen, A. V. Hertzel, D. A. Bernlohr, S. Kølvraa, K. Kristiansen, and S. Mandrup Lipid-binding proteins modulate ligand-dependent trans-activation by peroxisome proliferator-activated receptors and localize to the nucleus as well as the cytoplasm J. Lipid Res., November 1, 2000; 41(11): 1740 - 1751. [Abstract] [Full Text]
|
|
|
|
 |
|
 W. Yang, C. Rachez, and L. P. Freedman Discrete Roles for Peroxisome Proliferator-Activated Receptor gamma and Retinoid X Receptor in Recruiting Nuclear Receptor Coactivators Mol. Cell. Biol., November 1, 2000; 20(21): 8008 - 8017. [Abstract] [Full Text]
|
|
|
|
 |
|
 C. N. Ellis, J. Varani, G. J. Fisher, M. E. Zeigler, H. A. Pershadsingh, S. C. Benson, Y. Chi, and T. W. Kurtz Troglitazone Improves Psoriasis and Normalizes Models of Proliferative Skin Disease: Ligands for Peroxisome Proliferator-Activated Receptor-{gamma} Inhibit Keratinocyte Proliferation Arch Dermatol, May 1, 2000; 136(5): 609 - 616. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. E. Johnson, R. Vogel, S. J. Rutledge, G. Rodan, and A. Schmidt Thiazolidinedione Effects on Glucocorticoid Receptor-Mediated Gene Transcription and Differentiation in Osteoblastic Cells Endocrinology, July 1, 1999; 140(7): 3245 - 3254. [Abstract] [Full Text]
|
|
|
|
 |
|
 P. W. Young, D. R. Buckle, B. C. C. Cantello, H. Chapman, J. C. Clapham, P. J. Coyle, D. Haigh, R. M. Hindley, J. C. Holder, H. Kallender, et al. Identification of High-Affinity Binding Sites for the Insulin Sensitizer Rosiglitazone (BRL-49653) in Rodent and Human Adipocytes Using a Radioiodinated Ligand for Peroxisomal Proliferator-Activated Receptor gamma J. Pharmacol. Exp. Ther., February 1, 1998; 284(2): 751 - 759. [Abstract] [Full Text]
|
|
|
|
|
|
D. A. Ehrmann, D. J. Schneider, B. E. Sobel, M. K. Cavaghan, J. Imperial, R. L. Rosenfield, and K. S. Polonsky Troglitazone Improves Defects in Insulin Action, Insulin Secretion, Ovarian Steroidogenesis, and Fibrinolysis in Women with Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., July 1, 1997; 82(7): 2108 - 2116. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Mandrup and M. D. Lane Regulating Adipogenesis J. Biol. Chem., February 28, 1997; 272(9): 5367 - 5370. [Full Text] [PDF]
|
|
|
|
|
|
T.-A. C. Tai, C. Jennermann, K. K. Brown, B. B. Oliver, M. A. MacGinnitie, W. O. Wilkison, H. R. Brown, J. M. Lehmann, S. A. Kliewer, D. C. Morris, et al. Activation of the Nuclear Receptor Peroxisome Proliferator-activated Receptor gamma Promotes Brown Adipocyte Differentiation J. Biol. Chem., November 22, 1996; 271(47): 29909 - 29914. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Teboul, D. Gaillard, L. Staccini, H. Inadera, E.-Z. Amri, and P. A. Grimaldi Thiazolidinediones and Fatty Acids Convert Myogenic Cells into Adipose-like Cells J. Biol. Chem., November 24, 1995; 270(47): 28183 - 28187. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
